Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07099989Phase 1Active Not Recruiting

Pharmacokinetics of Zelquistinel in Fasted or Fed State

Role: collaborator

NCT06629402Phase 2Completed

Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)

Role: collaborator

NCT05571345Phase 1Completed

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

Role: collaborator

NCT06005402Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of CSX-1004

Role: collaborator

All 4 trials loaded